InterCure Closes 50% Botanico Tranche, Gains U.S. Cannabis Brands and AI Tech
INCR•InterCure closed the first 50% tranche of Botanico acquisition, issuing 2.47 million shares for exclusive U.S. cannabis genetics, premium brands and AI-driven production technology. The company is reviewing regulated U.S. medical markets after rescheduling to Schedule III and reported initial German revenues.
1. Botanico Acquisition First Tranche
InterCure completed the first tranche of its acquisition of Botanico Ltd., issuing 2,471,061 ordinary shares for a 50% interest. This closing grants exclusive access to award-winning U.S. cannabis genetics, premium brands and advanced AI-driven production technologies.
2. Additional Share Issuance
Upon meeting share purchase agreement conditions, InterCure will issue a further 2,470,073 ordinary shares to finalize the transaction, resulting in a total issuance of 4,941,134 shares in exchange for full acquisition of Botanico.
3. Strategic U.S. Review and German Expansion
Following federal rescheduling of medical cannabis to Schedule III, InterCure launched a strategic review of regulated U.S. medical markets. The company reported its first German revenues, appointed a German management and sales team and plans multiple product launches in the second half of the year.
